Results 31 to 40 of about 28,689 (318)
A key role for leukemia inhibitory factor in C26 cancer cachexia [PDF]
, 2015 Cachexia is an exacerbating event in many types of cancer that is strongly associated with a poor prognosis. We have identified cytokine, signaling, and transcription factors that are required for cachexia in the mouse C26 colon carcinoma model of cancer.
Jackman, Robert W. +2 more
core +1 more source
Trends in overall mortality among US veterans with primary myelofibrosis
BMC Cancer, 2023 Background Primary myelofibrosis [PMF] is a myeloproliferative neoplasm associated with reduced overall survival (OS). Management strategies for PMF have evolved over the last two decades, including approval of ruxolitinib as the first Janus kinase 1 ...
Tsewang Tashi +5 more
doaj +1 more source
Overcoming steroid resistance in T cell acute lymphoblastic leukemia [PDF]
, 2016 In a Perspective, Pieter Van Vlierberghe and Steven Goossens discuss Meijerink and colleagues' findings on steroid resistance in pediatric T cell acute lymphoblastic ...
Goossens, Steven +1 more
core +3 more sources
Experimental and Therapeutic Medicine, 2013 The aim of the present study was to assess the beneficial and harmful effects of ruxolitinib in patients with myelofibrosis (MF). The Cochrane databases, PubMed and Embase were searched for studies published up to October 2012. Randomised controlled trials assessing ruxolitinib versus a placebo or the best available therapy in patients with MF were ...
Jinjing Tan +8 more
openaire +4 more sources
Ruxolitinib withdrawal due to the COVID-19 [PDF]
Leukemia, 2021 Comment on the previously published paper.
Marko Lucijanic, Rajko Kusec
openaire +4 more sources
Recent progress of JAK inhibitors for hematological disorders
Immunological Medicine, 2023 JAK inhibitors are important therapeutic options for hematological disorders, especially myeloproliferative neoplasms. Ruxolitinib, the first JAK inhibitor approved for clinical use, improves splenomegaly and ameliorates constitutional symptoms in both ...
Keita Kirito
doaj +1 more source
Alopecia areata: a multifactorial autoimmune condition [PDF]
, 2019 Alopecia areata is an autoimmune disease that results in non-scarring hair loss, and it is clinically characterised by small patches of baldness on the scalp and/or around the body. It can later progress to total loss of scalp hair (Alopecia totalis) and/
Butcher, John P. +3 more
core +1 more source
Journal of Hematology & Oncology, 2017 Background Myelofibrosis (MF) is associated with a variety of burdensome symptoms and reduced survival compared with age-/sex-matched controls. This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor,
Srdan Verstovsek +13 more
doaj +1 more source
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study [PDF]
, 2019 Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with ...
Accurso V. +8 more
core +1 more source
Haematologica, 2019 Ruxolitinib is the front-line non-palliative treatment for myelofibrosis (MF). However, a significant number of patients lose or present suboptimal response, are resistant or have unacceptable toxicity.
Alicia Arenas Cortés +11 more
doaj +1 more source